Kliniczne wskaźniki dziedzicznych przyczyn i obciążenia leczeniem w opornej ogniskowej epilepsji: Kto najbardziej skorzysta z sekwencjonowania całego egzomu?
PubMed➕ 21.11.2026Epilepsy Behav
Clinical predictors of monogenic aetiology and pharmacotherapy burden in drug-resistant focal epilepsy: Who benefits most from whole exome sequencing?
W skrócie
Badacze sprawdzili, czy można przewidzieć, u których pacjentów z oporną ogniskową epilepsją przyczyna jest genetyczna, używając sekwencjonowania DNA. Okazało się, że zwykłe objawy choroby (wiek pojawienia się, częstość napadów, problemy z rozwojem) nie pozwalają dobrze przewidzieć, czy przyczyną jest mutacja genetyczna, dlatego trudno wskazać, którzy pacjenci powinni przejść drogim testem genetycznym. Liczba leków potrzebnych do kontroli napadów zależała od zaburzeń intelektualnych i częstości napadów, a nie od wyników testu genetycznego.
Oryginalny abstract (angielski)
BACKGROUND: Whole exome sequencing (WES) is of diagnostic value in focal drug-resistant epilepsy (FDRE) but is costly and not universally available. Identifying the clinical, imaging and electrophysiological features that predict a monogenic aetiology - and the determinants of pharmacotherapy burden - would allow rational selection of candidates for testing. We addressed both questions in a well-phenotyped Indian FDRE cohort. METHODS: One hundred and twenty-five patients with ILAE-defined FDRE underwent phenotyping and proband WES. Variants of uncertain significance (VUS) were re-evaluated against ACMG/AMP combining rules. Patients with a pathogenic or likely pathogenic (P/LP) variant (n = 12) were compared with WES-negative patients (n = 84); patients with only VUS (n = 29) were considered undiagnosed and described separately. Groups were compared using the Mann-Whitney U test (epilepsy-related variables) and Fisher's exact test (categorical features). Multiple linear regression identified independent predictors of the number of concurrent anti seizure medications (ASMs), and multivariable Firth-penalised logistic regression examined predictors of a P/LP diagnosis; effect sizes accompanied univariable associations. RESULTS: After reclassification, WES identified a P/LP variant in 12 patients (9.6 %); a further 29 (23.2 %) carried only VUS. No epilepsy-related variable (age of onset, epilepsy duration, seizure frequency, seizure-free interval, or ASM count) differed between P/LP and WES-negative patients. No categorical feature differed significantly: abnormal developmental history (42 % vs 21 %; OR 2.62, p = 0.152), positive family history (33 % vs 21 %; OR 1.83, p = 0.462) and intellectual deficits (25 % vs 15 %; OR 1.82, p = 0.415) were numerically more frequent in P/LP patients. Diagnostic yield was 14.7 % with abnormal development and 12.5 % with a positive family history, versus 7.7 % and 8.6 % in their absence. The number of concurrent ASMs was independently predicted by intellectual deficit (β = 0.813, p = 0.002) and log seizure frequency (β = 0.192, p = 0.030), but not by a P/LP variant (β = - 0.377, p = 0.261) or a VUS (β = - 0.316, p = 0.192). ASM adverse effects were infrequent (15/125) and unrelated to genetic status. CONCLUSIONS: Clinical presentation does not reliably distinguish patients with a P/LP diagnosis from WES-negative patients with FDRE. Abnormal development, family history and intellectual disability showed only non-significant enrichment of diagnostic yield in this P/LP group and require validation in larger cohorts. Pharmacotherapy burden was associated with intellectual disability and seizure frequency but was not explained by WES results.